Matches in SemOpenAlex for { <https://semopenalex.org/work/W2380493707> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W2380493707 abstract "Objective To observe the effect of rosuvastatin in primary hypertension with paroxysmal atrial fibrillation.Methods Eighty hypertensive cases with paroxysmal fibrillation atrial treated from June to December in 2012 were randomly divided into control group and treatment group,40 cases for each group.All patients started medication within 24 h after cardioversion of atrial fibrillation.Control group received oral aspirin(100 mg,l/d),nifedipine cntrolled release tablets(30 mg,l/d) and amiodarone(200 mg,three times per day for the first week,200 mg,twice per day for the second week,and 200 mg once daily for the third week).Treatment group received rosuvastatin 10 mg,once daily,in addition.If blood pressure could not be controlled.indapamide tablets was added,2.5-5 mg,once daily.Both groups were treated for 12 months,and compared for clinical efficacy,recurrence rate of paroxysmal atrial fibrillation,incidence of persistent atrial fibrillation,left atrial diameter,blood Hpid,hsCRP,renin,the level of Angll expression,and the function of liver and kidney.Measurement data were processed by t-test.count data by x~2 test.the result of P0.05 showed significant difference.Results The total effective rate was 67.5%in control group and 92.5%in treatment group.In control group.recurrence of paroxysmal atrial fibrillation accounted for 32.5%,persistent or permanent atrial fibrillation for15%;in treatment group.recurrence of paroxysmal atrial fibrillation accounted for 7.5%and 2.5%for persistent or permanent atrial fibrillation.After treatment.left atrial diameter and blood lipid indicatorsfTC,LDL-C,HDL-C,TG) were(35.42 ± 0.36)mm,(4.33 ±0.79)mmol/L,(2.80 ± 0.21)mmol/L,(0.99 ± 0.21)mmol/L and(2.04 ± 0.48)mmol/L respectively in control group and(33.10 ± 0.45)mm,(3.24 ± 0.60)mmol/L,(1.44 ± 0.20)mmol/L,(l.26 ± 0.17)mmol/L and(1.13 ± 0.35)mmol/L respectively in treatment group.and the difference was statistically significant(P0.05).After treatment,hs-CRP,renin,Ang II were(3.52 ± 0.12)mg/L,(0.47 ±0.27)ng·ml~(-1)·h~(-1)and(60.94±21.44)pg/ml respectively in control group and(2.98 ±0.11)mg/L,(0.36 ± 0.32)ng·ml~(-1)·h~(-1) and(50.89 ± 30.22)pg/ml respectively in treatment group.the difference was statistically significant(P0.05).Conclusion Rosuvastatin for primary hypertension with paroxysmal atrial fibrillation can reduce the recurrence of paroxysmal atrial fibrillation,the incidence of persistent atrial fibrillation.reduce the left atrial diameter,lower serum levels of hs-CRP,rennin and AngII,improving clinical efficacy.which is worthy of clinical application." @default.
- W2380493707 created "2016-06-24" @default.
- W2380493707 creator A5010240118 @default.
- W2380493707 date "2014-01-01" @default.
- W2380493707 modified "2023-09-23" @default.
- W2380493707 title "Study of rosuvastatin on primary hypertension with paroxysmal atrial fibrillation" @default.
- W2380493707 hasPublicationYear "2014" @default.
- W2380493707 type Work @default.
- W2380493707 sameAs 2380493707 @default.
- W2380493707 citedByCount "0" @default.
- W2380493707 crossrefType "journal-article" @default.
- W2380493707 hasAuthorship W2380493707A5010240118 @default.
- W2380493707 hasConcept C120665830 @default.
- W2380493707 hasConcept C121332964 @default.
- W2380493707 hasConcept C126322002 @default.
- W2380493707 hasConcept C164705383 @default.
- W2380493707 hasConcept C2777289489 @default.
- W2380493707 hasConcept C2778094803 @default.
- W2380493707 hasConcept C2779161974 @default.
- W2380493707 hasConcept C2780499067 @default.
- W2380493707 hasConcept C2985986913 @default.
- W2380493707 hasConcept C42219234 @default.
- W2380493707 hasConcept C61511704 @default.
- W2380493707 hasConcept C71924100 @default.
- W2380493707 hasConceptScore W2380493707C120665830 @default.
- W2380493707 hasConceptScore W2380493707C121332964 @default.
- W2380493707 hasConceptScore W2380493707C126322002 @default.
- W2380493707 hasConceptScore W2380493707C164705383 @default.
- W2380493707 hasConceptScore W2380493707C2777289489 @default.
- W2380493707 hasConceptScore W2380493707C2778094803 @default.
- W2380493707 hasConceptScore W2380493707C2779161974 @default.
- W2380493707 hasConceptScore W2380493707C2780499067 @default.
- W2380493707 hasConceptScore W2380493707C2985986913 @default.
- W2380493707 hasConceptScore W2380493707C42219234 @default.
- W2380493707 hasConceptScore W2380493707C61511704 @default.
- W2380493707 hasConceptScore W2380493707C71924100 @default.
- W2380493707 hasLocation W23804937071 @default.
- W2380493707 hasOpenAccess W2380493707 @default.
- W2380493707 hasPrimaryLocation W23804937071 @default.
- W2380493707 hasRelatedWork W1967701161 @default.
- W2380493707 hasRelatedWork W1974132805 @default.
- W2380493707 hasRelatedWork W2004137064 @default.
- W2380493707 hasRelatedWork W2109017956 @default.
- W2380493707 hasRelatedWork W2168795118 @default.
- W2380493707 hasRelatedWork W2263890878 @default.
- W2380493707 hasRelatedWork W2352589853 @default.
- W2380493707 hasRelatedWork W2359314791 @default.
- W2380493707 hasRelatedWork W2363608265 @default.
- W2380493707 hasRelatedWork W2364440833 @default.
- W2380493707 hasRelatedWork W2366849936 @default.
- W2380493707 hasRelatedWork W2376999633 @default.
- W2380493707 hasRelatedWork W2384248420 @default.
- W2380493707 hasRelatedWork W2392022856 @default.
- W2380493707 hasRelatedWork W3029764497 @default.
- W2380493707 hasRelatedWork W3030817658 @default.
- W2380493707 hasRelatedWork W3030992047 @default.
- W2380493707 hasRelatedWork W3031261273 @default.
- W2380493707 hasRelatedWork W3032298243 @default.
- W2380493707 hasRelatedWork W3032566521 @default.
- W2380493707 isParatext "false" @default.
- W2380493707 isRetracted "false" @default.
- W2380493707 magId "2380493707" @default.
- W2380493707 workType "article" @default.